Tag: Incyte Corp

Home / Incyte Corp

Categories

Ruxolitinib is approved for chronic graft-versus-host disease

October 2021: After failure of one or two lines of systemic therapy, the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte Corp.) for chronic graft-versus-host disease (cGVHD) in adult...
incyte-corp

Scan the code